Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutational analysis of the tumor suppressor Smad2 in acute lymphoid and myeloid leukemia.

Leukemia - 1 Jul 1998

Wieser R, Gruber B, Rieder H, Fonatsch C

Abstract excerpt

Smad4 is a tumor suppressor that is inactivated in about 50% of pancreatic carcinomas. Mutations in this gene have also been found with variable, yet much lower frequency in other tumor types and were absent from a large number of samples from patients with hematological malignancies. Smad2 shows considerable sequence similarity with Smad4 and cooperates with it in the growth inhibitory TGF-beta pathway. Smad2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Base Sequence
Share to DNA-Binding Proteins
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Gene Deletion

Share to Mutation

Share to Polymerase Chain Reaction

Share to Polymorphism, Single-Stranded Conformational

Source

Identifiers

PMID: 9665198
DOI: 10.1038/sj.leu.2401073

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational analysis of the tumor suppressor Smad2 in acute lymphoid and myeloid leukemia.PMID 9665198Read ↗

Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis.Semantic proximity Read ↗

Somatic alterations of the SMAD-2 gene in human colorectal cancersSemantic proximity Read ↗

Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor β signaling by targeting Smads to the ubiquitin–proteasome pathwaySemantic proximity Read ↗

Identification of Smad2, a Human Mad-related Protein in the Transforming Growth Factor β Signaling PathwaySemantic proximity Read ↗

Mechanism for mutational inactivation of the tumor suppressor Smad2.Semantic proximity Read ↗

Frequency of Smad gene mutations in human cancers.Semantic proximity Read ↗

Identification of germline alterations of the mad homology 2 domain of SMAD3 and SMAD4 from the Ontario site of the breast cancer family registry (CFR).Semantic proximity Read ↗

Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colonSemantic proximity Read ↗

Smad5, a tumor suppressor candidate at 5q31.1, is hemizygously lost and not mutated in the retained allele in human leukemia cell line HL60.Semantic proximity Read ↗

Loss of Smad3 in Acute T-Cell Lymphoblastic LeukemiaSemantic proximity Read ↗

Cloning of a novel signaling molecule, AMSH-2, that potentiates transforming growth factor β signalingSemantic proximity Read ↗

Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.